Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Garadacimab in the Prophylactic Treatment of Hereditary Angioedema
NCT04739059Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Mar 2021
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of garadacimab in hereditary angioedema (HAE), sponsored by CSL Limited. Started Mar 2021; status: completed.
02
Drugs
garadacimab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT04739059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04739059.